Veracyte IPO

Veracyte completed its IPO in October 2013, going public on the NASDAQ under the ticker symbol VCYT at $12 per share. The genomic diagnostics company raised approximately $46 million in its initial public offering. Since going public, the stock has experienced significant growth, reaching highs above $80 in 2021, though it has also seen volatility typical of biotech stocks. As a public company, Veracyte has continued to expand its diagnostic test portfolio and has made several acquisitions to broaden its capabilities in cancer diagnostics. The company has grown its revenue base and expanded internationally while developing new genomic tests. The stock performance has generally reflected the company's progress in commercializing its diagnostic tests and expanding market adoption, though it remains subject to the volatility common in the diagnostics and biotech sectors.